• Yiping Li, Allan R Wang, and Gary K Steinberg.
• Department of Neurosurgery and Stanford Stroke Center, Stanford University School of Medicine and Stanford Health Center, Stanford, California, USA.
• World Neurosurg. 2022 Apr 1; 160: e381-e387.

BackgroundPerioperative management of blood pressure in patients undergoing surgical revascularization for moyamoya disease (MMD) remains a controversial topic. We evaluated the safety and efficacy of induced hypertension and hypervolemia (IHH) in preventing neurologic complications during the perioperative period after direct surgical revascularization in a large hemorrhagic-onset moyamoya disease (HOMMD) cohort.MethodsWe retrospectively reviewed a prospectively managed departmental database of all HOMMD patients treated between 1987 and 2019. The study included 122 direct surgical revascularization patients. Patients were separated into groups on the basis of the presence or absence of IHH therapy and evaluated for occurrence of 30-day risk of transient neurologic events (TNEs), ischemic, and hemorrhagic complications.ResultsTwo-hundred and three revascularization procedures were performed on 122 patients for HOMMD treatment. Nineteen TNEs (9.4% of procedures) were observed in 18 (14.8%) patients. Two patients (1.6% and 1.0% of procedures) suffered from ischemic complications and 1 (0.8% and 0.5% of procedures) from hemorrhagic complications. No differences between groups in the severity, duration of TNEs, or length of hospital stay were noted. No patient in the IHH therapy group experienced a recurring TNE or readmission after discharge; however, this was not statistically significant owing to the small sample size. There were no differences in the rates of ischemic or hemorrhagic complications between groups with or without IHH therapy (P = 0.46 and 0.54, respectively).ConclusionsInduced hypertension and hypervolemia appear safe in HOMMD. There were no significant differences in complication or TNE rates between the groups with or without IHH therapy. While we believe it is important to employ IHH therapy in MMD patients who present with ischemic symptoms, these findings suggest that prophylactic IHH therapy may not be necessary in MMD patients presenting with hemorrhage.Copyright © 2022 Elsevier Inc. All rights reserved.

19 keywords...

hide…